Thyrocare Technologies Limited , a prominent player in the diagnostic services sector, has announced significant developments following the recent shareholder approvals for key resolutions.

Bonus Share Issue Details

Thyrocare Technologies has fixed November 28, 2025 as the record date for determining shareholder eligibility for bonus shares. The company plans to issue bonus shares in a 2:1 ratio, meaning each shareholder may receive 2 bonus shares of Rs. 10 face value for every 1 existing share held. The bonus shares are scheduled to be allotted on December 1, 2025, and may be available for trading from December 2, 2025.

Previous Shareholder Approvals

This announcement follows the shareholder approval received earlier for three key resolutions through a postal ballot:

1. Increase in Authorized Share Capital:

   • 99.9997% votes in favor
   • 0.0003% votes against

2. Alteration of Articles of Association:

   • 99.9993% votes in favor
   • 0.0007% votes against

3. Issuance of Bonus Shares:

   • 99.9998% votes in favor
   • 0.0002% votes against

Voting Participation

The postal ballot saw participation from shareholders:

Implications for Investors

The approval and implementation of these resolutions may have several implications for Thyrocare Technologies and its shareholders:

1. Increased Authorized Share Capital: This move may provide the company with greater flexibility for future fundraising or corporate actions.

2. Alteration of Articles of Association: While specific details are not provided, this change could potentially update the company's governance structure or operational guidelines.

3. Bonus Share Issuance: This decision is expected to increase the number of outstanding shares without changing the company's market capitalization, potentially improving stock liquidity.

The shareholder support across all resolutions indicates confidence in the company's strategic decisions. With the record date now set, investors and market watchers may closely monitor the implementation of the bonus share issuance and its potential impact on Thyrocare Technologies' stock performance in the coming months.

API Holdings Limited, the parent company of PharmEasy, has fully repaid and redeemed its Series 2 Non-Convertible Debentures (NCDs) worth ₹500 crore on October 28, 2025. This significant financial move, however, has not altered the existing share pledge arrangement involving Thyrocare Technologies Limited .

Unchanged Pledge Status

Despite the redemption of the Series 2 NCDs, there is no change in the number of encumbered shares of Thyrocare Technologies Limited held by Docon Technologies Private Limited, a subsidiary of API Holdings. Docon continues to maintain a pledge on 3,23,23,232 shares of Thyrocare, representing 60.93% of the total share capital.

Pledge Details

The pledged shares remain under the custody of Catalyst Trusteeship Limited, which acts as the Debenture Trustee. This pledge was initially created as security for corporate guarantees extended by Docon to secure API Holdings' obligations related to facilities availed through the issuance of unlisted, unrated, secured, redeemable non-convertible debentures.

Remaining Debentures

While the Series 2 NCDs have been fully redeemed, it's noteworthy that Series 1 Debentures with an aggregate nominal value of up to ₹12,000 million remain outstanding. These debentures are held by multiple investors, including:

Several other institutional and individual investors also hold portions of these debentures.

Implications

The redemption of the Series 2 NCDs by API Holdings demonstrates the company's ability to meet its debt obligations. However, the unchanged status of the Thyrocare share pledge indicates that the company continues to utilize these shares as collateral for its remaining financial commitments.

This development comes as part of API Holdings' ongoing financial management strategies, balancing debt repayment with maintaining necessary securities for its outstanding obligations. The company's actions suggest a focus on debt reduction while retaining the flexibility provided by the pledged Thyrocare shares for its continuing operations and financial needs.